Is COR or REGN cheaper?

On trailing earnings, REGN is cheaper: COR trades at a 21.60 P/E and REGN at 14.92.

Which has grown faster, COR or REGN?

Over the past five years, COR grew revenue faster — COR at a 10.86% CAGR versus REGN at 10.16%.

Does COR or REGN pay a bigger dividend?

COR yields 0.83% and REGN yields 0.59% based on trailing dividends and the latest price.

Is COR or REGN more profitable?

REGN runs the higher net margin — COR at 0.78% versus REGN at 29.65%.

Which has been the better investment, COR or REGN?

Over the past 10-year, COR delivered the higher annualized total return — COR at 17.22% versus REGN at 5.19%. Past performance doesn't predict future results.

Cencora, Inc. (COR) vs Regeneron Pharmaceuticals, Inc. (REGN)

REGN leads on 10 of 17 compared metrics.

A side-by-side comparison of Cencora, Inc. and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Regeneron Pharmaceuticals, Inc.

$63.06B

$612.14Healthcare

Total return — COR vs REGN

growth of $100 · last 30y

COR +6803.7%REGN +3436.3%COR compounded faster

COR REGN

COR vs REGN: by the numbers

•REGN is the larger company ($63.06B vs $54.80B market cap).
•REGN trades at the lower earnings multiple (14.92 vs 21.60 P/E).
•REGN converts more revenue to profit (29.65% vs 0.78% net margin).
•COR grew revenue faster over the past five years (10.86% vs 10.16% CAGR).
•COR pays the higher dividend yield (0.83% vs 0.59%).

Which is better, COR or REGN?

Metric tally: COR 7 · REGN 10

It depends on what you're optimizing for:

ValueREGN(lower P/E)

GrowthCOR(faster 5Y revenue CAGR)

IncomeCOR(higher dividend yield)

QualityCOR(higher ROIC)

Valuation

Metric	COR	REGN
P/E ratio	21.60	14.92●
Forward P/E	14.22	11.30●
P/S ratio	0.17●	4.42
P/B ratio	16.20	2.10●
PEG ratio	7.05	3.38●
EV / EBITDA	13.05	11.43●
FCF yield	2.83%	6.30%●

Profitability

Metric	COR	REGN
Gross margin	3.47%	84.55%●
Operating margin	1.28%	24.32%●
Net margin	0.78%	29.65%●
ROE	75.01%●	14.08%
ROIC	13.23%●	8.51%

Dividends

Metric	COR	REGN
Dividend yield	0.83%●	0.59%
Payout ratio	29.30%	8.45%

Growth (annualized)

Metric	COR	REGN
Revenue CAGR (5Y)	10.86%●	10.16%
EPS CAGR (5Y)	11.97%●	5.70%
FCF CAGR (5Y)	3.95%	15.42%●
Total return CAGR (5Y)	19.86%●	3.26%

Frequently asked

Which is better, COR or REGN?: It depends on your goal. value: REGN (lower P/E); growth: COR (faster 5Y revenue CAGR); income: COR (higher dividend yield); quality: COR (higher ROIC). Across all compared metrics, REGN leads 10 to 7.
Is COR or REGN cheaper?: On trailing earnings, REGN is cheaper: COR trades at a 21.60 P/E and REGN at 14.92.
Which has grown faster, COR or REGN?: Over the past five years, COR grew revenue faster — COR at a 10.86% CAGR versus REGN at 10.16%.
Does COR or REGN pay a bigger dividend?: COR yields 0.83% and REGN yields 0.59% based on trailing dividends and the latest price.
Is COR or REGN more profitable?: REGN runs the higher net margin — COR at 0.78% versus REGN at 29.65%.
Which has been the better investment, COR or REGN?: Over the past 10-year, COR delivered the higher annualized total return — COR at 17.22% versus REGN at 5.19%. Past performance doesn't predict future results.

Go deeper

Full COR analysis Full REGN analysis Interactive comparison tool

Dig into the metrics

Cencora P/E ratio Regeneron Pharmaceuticals P/E ratio Cencora dividend yield Regeneron Pharmaceuticals dividend yield Cencora ROE Regeneron Pharmaceuticals ROE Cencora operating margin Regeneron Pharmaceuticals operating margin Cencora revenue growth Regeneron Pharmaceuticals revenue growth Cencora free cash flow Regeneron Pharmaceuticals free cash flow

Cencora & Regeneron Pharmaceuticals appear in these rankings

Highest ROE Stocks Highest FCF Yield Stocks Best 10-Year Total Return Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 13, 2026.